Content for this article was provided by EVERSANA’s Asia Pacific team.
The global burden of infectious diseases is increasing, especially for severe diseases such as invasive aspergillosis, a rare infectious disease, which has a 90% mortality rate. These diseases have poor prognoses and high mortality rates. Disease severity and mortality rates have been increased by anti-microbial/antibiotic resistance. Large gaps exist in the pipeline, with only 18% of antibiotic clinical development being innovative. Manufacturers face challenges in addressing the lack of differentiation in their drugs. In addition to clinical unmet needs, different markets offer a variety of access challenges.
Complete the form below to learn more about US, EU5 and APAC access challenges and how these challenges can be reshaped
EVERSANA employs a team of over 6000 professionals across 20+ locations around the world. From industry-leading patient service and adherence support to global pricing and revenue management, our team informs the strategies that matter…